安徽医药
安徽醫藥
안휘의약
ANHUI MEDICAL AND PHARMACEUTICAL JOURNAL
2014年
12期
2363-2364,2365
,共3页
糖尿病心肌病%瑞舒伐他汀%超敏C反应蛋白%脑钠肽
糖尿病心肌病%瑞舒伐他汀%超敏C反應蛋白%腦鈉肽
당뇨병심기병%서서벌타정%초민C반응단백%뇌납태
diabetic cardiomyopathies%rosuvastatin%hypersensitive C-reactive protein%brain natriuretic peptide
目的:探讨瑞舒伐他汀对糖尿病心肌病患者脑钠肽( BNP)和超敏C反应蛋白( hs-CRP)的影响。方法将60例糖尿病心肌病患者随机分为对照组(30例)和治疗组(30例)。对照组在治疗过程中予严格控制血糖并给予抗心衰规范化治疗;治疗组在对照组治疗基础上加用瑞舒伐他汀(10 mg · d-1)治疗。所有患者均在治疗前及治疗后12周测定左室舒张末期内径(LVDd)、左室射血分数(LVEF)、血清低密度脂蛋白(LDL-C)及血浆脑钠肽前体检氨基端片段(NT-proBNP,简称BNP)和血清超敏C反应蛋白( hs-CRP)。结果12周后所有患者LVDd、LVEF治疗前后无统计学差异,两组间降幅差异亦无统计学意义[LVDd:(-0.7±2.2) vs (-1.5±1.5),P=0.779;LVEF:(0.6±1.4) vs (0.3±1.5),P=0.589]。治疗组较对照组的LDL-C、BNP及hs-CRP的降低幅度均有显著增加[LDL-C:(-1.77±0.29) vs (0.04±0.24),P=0.000;BNP:(-360.5±414.0) vs (-15.1±217.3),P=0.008;hs-CRP:(-0.84±0.65) vs (-0.17±0.40),P=0.002]。结论瑞舒伐他汀钙能显著降低糖尿病心肌病患者的炎症介质及脑钠肽水平,提示该药改善其心功能。
目的:探討瑞舒伐他汀對糖尿病心肌病患者腦鈉肽( BNP)和超敏C反應蛋白( hs-CRP)的影響。方法將60例糖尿病心肌病患者隨機分為對照組(30例)和治療組(30例)。對照組在治療過程中予嚴格控製血糖併給予抗心衰規範化治療;治療組在對照組治療基礎上加用瑞舒伐他汀(10 mg · d-1)治療。所有患者均在治療前及治療後12週測定左室舒張末期內徑(LVDd)、左室射血分數(LVEF)、血清低密度脂蛋白(LDL-C)及血漿腦鈉肽前體檢氨基耑片段(NT-proBNP,簡稱BNP)和血清超敏C反應蛋白( hs-CRP)。結果12週後所有患者LVDd、LVEF治療前後無統計學差異,兩組間降幅差異亦無統計學意義[LVDd:(-0.7±2.2) vs (-1.5±1.5),P=0.779;LVEF:(0.6±1.4) vs (0.3±1.5),P=0.589]。治療組較對照組的LDL-C、BNP及hs-CRP的降低幅度均有顯著增加[LDL-C:(-1.77±0.29) vs (0.04±0.24),P=0.000;BNP:(-360.5±414.0) vs (-15.1±217.3),P=0.008;hs-CRP:(-0.84±0.65) vs (-0.17±0.40),P=0.002]。結論瑞舒伐他汀鈣能顯著降低糖尿病心肌病患者的炎癥介質及腦鈉肽水平,提示該藥改善其心功能。
목적:탐토서서벌타정대당뇨병심기병환자뇌납태( BNP)화초민C반응단백( hs-CRP)적영향。방법장60례당뇨병심기병환자수궤분위대조조(30례)화치료조(30례)。대조조재치료과정중여엄격공제혈당병급여항심쇠규범화치료;치료조재대조조치료기출상가용서서벌타정(10 mg · d-1)치료。소유환자균재치료전급치료후12주측정좌실서장말기내경(LVDd)、좌실사혈분수(LVEF)、혈청저밀도지단백(LDL-C)급혈장뇌납태전체검안기단편단(NT-proBNP,간칭BNP)화혈청초민C반응단백( hs-CRP)。결과12주후소유환자LVDd、LVEF치료전후무통계학차이,량조간강폭차이역무통계학의의[LVDd:(-0.7±2.2) vs (-1.5±1.5),P=0.779;LVEF:(0.6±1.4) vs (0.3±1.5),P=0.589]。치료조교대조조적LDL-C、BNP급hs-CRP적강저폭도균유현저증가[LDL-C:(-1.77±0.29) vs (0.04±0.24),P=0.000;BNP:(-360.5±414.0) vs (-15.1±217.3),P=0.008;hs-CRP:(-0.84±0.65) vs (-0.17±0.40),P=0.002]。결론서서벌타정개능현저강저당뇨병심기병환자적염증개질급뇌납태수평,제시해약개선기심공능。
Objective To investigate the effect of rosuvastatin on brain natriuretic peptide and hypersensitive C -reactive protein in pa-tients with diabetic cardiomyopathies .Methods Sixty patients with diabetic cardiomyopathies were randomized into 2 groups:the con-trol group(n=30) and the intervention group(n=30).Management of blood glucose and heart failure was performed in the 2 groups, with rosuvastatin(10 mg· d-1 ) added to the patients in the treatment group .LVDd,LVEF,LDL-C,BNP and hs-CRP measurement was performed in every patient before and 12 weeks after initiation of the study .Results After 12 weeks of treatment ,compared to the con-trol group,the levels of LDL-C,BNP and hs-CRP were significantly decreased in treatment group [LDL-C:(-1.77 ±0.29) vs (0.04 ±0.24),P=0.000;BNP:(-360.5 ±414.0) vs (-15.1 ±217.3),P=0.008;hs-CRP:(-0.84 ±0.65) vs ( -0.17 ±0.40), P=0.002].However,there were no significant differences in the LVDd and LVEF between control and treatment group ,[LVDd:(-0.7 ±2.2) vs (-1.5 ±1.5),P=0.779;LVEF:(0.6 ±1.4) vs (0.3 ±1.5),P=0.589].Conclusions Rosuvastatin signifi-cantly reduces the inflammatory mediators and brain natriuretic peptide levels in patients with diabetic cardiomyopathies ,which indi-cates that this medicine probably improves the heart function of the patients .